Results 21 to 30 of about 531,678 (162)
Yersinia Outer Membrane Vesicles as Potential Vaccine Candidates in Protecting against Plague
Biomolecules, 2020 Despite the relatively low incidence of plague, its etiological agent, Yersinia pestis, is an exceptional epidemic danger due to the high infectivity and mortality of this infectious disease. Reports on the isolation of drug-resistant Y.
Andrey A. Byvalov +4 more
doaj +1 more source
Changes in Biomodels in Response to Recombinant Protective Anthrax Antigen Inoculation
Проблемы особо опасных инфекций, 2013 one. The data obtained has substantiated the lack of an expressed damaging effect of the recombinant protective antigen on the cells and tissues of the macroorganism, as well as possibility of its application as one of the core components of the ...
P. Yu. Popova +5 more
doaj +1 more source
Проблемы особо опасных инфекций, 2012 Assessment of immunogenicity and biological safety of protective antigen preparation obtained from asporogenic recombinant producer, B. anthracis 55ΔTPA-1(Spo-), is made on the mice (BALB/c species) and Guiney pigs models.
P. Yu. Popova +9 more
doaj +1 more source
Toxins, 2013 Inhaled Bacillus anthracis spores germinate and the subsequent vegetative growth results in bacteremia and toxin production. Anthrax toxin is tripartite: the lethal factor and edema factor are enzymatic moieties, while the protective antigen (PA) binds ...
Cecil Chen +6 more
doaj +1 more source
Vaccines Against Anthrax – Selected Research
Postępy Mikrobiologii, 2022 New strategies in the development of anthrax vaccines and therapeutics have been presented. Recently, considerable progress has been made in the finding of new drugs and suitable therapy for anthrax.
Żakowska Dorota +4 more
doaj +1 more source
Инфекция и иммунитет, 2019 Currently, live anthrax vaccine has been used for vaccine prophylaxis in Russia and neighbor countries for seve ral decades, but precise mechanism of post-vaccination protection mechanism remains unclear. Here, we provide data on examining serum antibody
V. V. Firstova +6 more
doaj +1 more source
Vaccinal Preventon of Anthrax in the Russian Federation and Its Immediate Prospects
Вестник войск РХБ защиты, 2023 The purpose of the work is to show the possibilities of vaccine prophylaxis of anthrax in the Russian Federation and its immediate prospects. The article is dedicated to the vaccine preparations, available in Russia and abroad in the arsenal of medical ...
A. N. Shevtsov +3 more
doaj +1 more source
VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines [PDF]
BMC Bioinformatics, 2007 Vaccine development in the post-genomic era often begins with the in silico screening of genome information, with the most probable protective antigens being predicted rather than requiring causative microorganisms to be grown. Despite the obvious advantages of this approach--such as speed and cost efficiency--its success remains dependent on the ...
Irini A. Doytchinova, Darren R. Flower
openaire +4 more sources
Virulence, 2020 Burkholderia mallei is a highly pathogenic bacterium that causes the fatal zoonosis glanders. The organism specifies multiple membrane proteins, which represent prime targets for the development of countermeasures given their location at the host ...
Jeremy S. Dyke +6 more
doaj +1 more source
Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics
Toxins, 2023 Anthrax toxin is a critical virulence factor of Bacillus anthracis. The toxin comprises protective antigen (PA) and two enzymatic moieties, edema factor (EF) and lethal factor (LF), forming bipartite lethal toxin (LT) and edema toxin (ET).
Weiming Ouyang +3 more
doaj +1 more source